Vonvendi Or Veyvondi Market Report 2026

Vonvendi Or Veyvondi Market Overview

• The Vonvendi Or Veyvondi market growth in the historic period has been driven by increasing diagnosis rates of von willebrand disease, availability of recombinant protein therapies • Market expansion is supported by increasing focus on personalized rare disease treatments, rising investments in recombinant biologics • Growth Driver: Increasing Clinical Trials Is Driving The Growth Of The Market • Market Trend: FDA Approval Drives Growth Through Wider Patient Eligibility • North America was the largest region in 2025.

What Is Covered Under Vonvendi Or Veyvondi Market?

Vonvendi, or veyvondi refers to a brand name for recombinant von Willebrand factor (rVWF), a medication used to treat and manage bleeding episodes in patients with von Willebrand disease (VWD). Vonvendi is utilized as a treatment to manage bleeding episodes in patients with von Willebrand disease by replacing the deficient or dysfunctional von Willebrand factor. The main types of clinical indications in vonvendi or veyvondi are von willebrand disease type 1, von willebrand disease type 2, and von willebrand disease type 3. Type 1 von Willebrand disease (VWD) is the most prevalent form, affecting 60% to 80% of individuals with the condition. It is distributed through hospitals, retail pharmacies, online pharmacies, and specialty pharmacies. And catering to various end users such as adults, pediatrics, and geriatric patients

What Is The Vonvendi Or Veyvondi Market Growth Forecast?

The growth in the forecast period can be attributed to increasing focus on personalized rare disease treatments, rising investments in recombinant biologics, expansion of home-based infusion therapies, growing specialty pharmacy penetration, advancements in protein engineering technologies. Major trends in the forecast period include increasing use of recombinant plasma-free therapies, rising adoption of targeted bleeding disorder treatments, growing preference for on-demand bleeding management, expansion of specialty pharmacy distribution, enhanced focus on personalized hematology care.

What Are The Drivers Of The Vonvendi Or Veyvondi Market?

The increasing clinical trials are expected to propel the growth of the vonvendi or veyvondi market going forward. Clinical trials refer to research studies that evaluate the safety, efficacy, and potential side effects of new treatments, medications, or medical devices. The increasing clinical trials are due to advancements in medical research and technology, the rising incidence of chronic and complex diseases, and an aging global population that demands new treatments. Clinical trials support vonvendi or veyvondi by providing rigorous scientific validation of their safety and efficacy, enabling regulatory approvals, fostering trust among healthcare providers and patients, and paving the way for optimized treatment protocols and broader accessibility for managing von Willebrand disease. For instance, in December 2024, according to a report published by the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, the number of industry clinical trials initiated increased slightly from 411 in 2022 to 426 in 2023, suggesting a modest recovery after several years. Therefore, the increasing clinical trials are driving the growth of the vonvendi or veyvondi industry. The growing awareness of bleeding disorders is expected to propel the growth of the vonvendi or veyvondi market going forward. Bleeding disorders are conditions that impair the blood's ability to clot appropriately to excessive bleeding or difficulty stopping bleeding after injury. The growing awareness of bleeding disorders is crucial for early diagnosis, better management, and improved quality of life for individuals affected while promoting greater understanding and support within communities and healthcare systems. Vonvendi or veyvondi helps manage bleeding disorders, particularly in individuals with von willebrand disease, by providing a recombinant form of von willebrand factor to increase platelet adhesion and clot formation, thus reducing the frequency and severity of bleeding episodes and promoting better control over bleeding symptoms associated with this inherited condition. For instance, in Aoril 2025, according to Pfizer Inc a US-based pharmaceutical and biotechnology corporation, in the 2023/24 period, the UK haemophilia A and B patient population exceeded 11,800 individuals, underscoring a sizable and clinically significant treated population. Therefore, growing awareness of bleeding disorders is driving the growth of the vonvendi or veyvondi industry.

Key Players In The Global Vonvendi Or Veyvondi Market

Major companies operating in the vonvendi or veyvondi market are Takeda Pharmaceutical Co. Ltd.

Global Vonvendi Or Veyvondi Market Trends and Insights

Major companies operating in the von Willebrand factor replacement market are prioritising technological advancement in the form of indication expansion and regulatory lifecycle management, such as submitting and executing supplemental filings supported by broader clinical and real-world evidence to extend prophylactic and pediatric uses. Indication expansion and regulatory lifecycle management refers to the coordinated clinical, regulatory and evidentiary activities pivotal or extension trials, real-world evidence generation, priority-review engagements and updated safety-monitoring frameworks that enable a product to move from narrower, often adult-only or on-demand approvals into broader routine prophylaxis and paediatric indications, thereby enlarging the clinically eligible population and changing treatment paradigms. For instance, in September 2025, Takeda Pharmaceutical Company Limited, a Japan-headquartered global biopharmaceutical company, announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application (sBLA) for VONVENDI, expanding its indication to include routine prophylaxis to reduce bleeding-episode frequency in adults with all types of von Willebrand disease (including types 1 and 2) and to allow on-demand and perioperative management of bleeding in paediatric patients. This expanded approval broadens the therapy’s authorised use across more patient groups, strengthens its positioning as a recombinant VWF option for both adults and children, and creates new opportunities for prophylactic treatment strategies that can reduce bleeding frequency and improve patient quality of life.

What Defines the Vonvendi Or Veyvondi Market?

The vonvendi or veyvondi market consists of sales of on-demand treatment and perioperative management. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vonvendi Or Veyvondi Market Report 2026?

The vonvendi or veyvondi market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vonvendi or veyvondi industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.